
Overview: The pharmaceutical industry's daily monitor, with emphasis on post-marketing topics, market development, and corporate earnings.
Newsletter Subscribers: 60,000+
Publishing Schedule: daily
Audience: Senior pharmaceutical industry executives, project managers, brand managers, and other insiders at pharmaceuticals.
Reader Demographics
Company Type
Pharmaceutical - 33%
Biotechnology - 11%
Academia / Government Research / Other Research - 7%
Consulting - 18%
Marketing / Media - 5%
Finance / PE / VC - 5%
Other - 13%
Job Function
Corporate Management (CEO, CFO, COO, CIO, SVP, VP) - 26%
R&D and Lab Management - 23%
Sales & Marketing - 15%
Product/Brand Management - 6%
Licensing / Business Development - 4%
Finance - 5%
Manufacturing / Production - 3%
Regulatory / Labeling / Safety - 3%
IT - 1%
Other - 15%
Region
North America - 80%
Europe - 14%
Asia-Pacific - 4%
Central & South America - 1%
69% of FiercePharma readers have an advanced degree.
64% of FiercePharma readers supervise others.
64% of FiercePharma readers make purchasing decisions.
Enter your contact information to see current rates and packages.
FiercePharma Audience - Top 25 Ranked by Readership
- Pfizer
- GSK
- Merck
- Amgen
- J&J
- Abbott
- Bristol Myers Squibb
- Genentech
- Hoffman LaRoche
- Eli Lilly
- Schering-Plough
- Aventis
- AstraZeneca
- Boehringer Ingelheim
- Bayer
- Sanofi
- Baxter
- Allergan
- Novartis
- MedImmune
- Gilead
- Takeda
- Genzyme
- Cephalon
- Novo Nordisk
- Vertex
- Procter & Gamble
- Elan
- Covance

